S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:ISRIsoRay Stock Price, Forecast & News

$0.69
0.00 (-0.10 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.66
Now: $0.69▼
$0.70
50-Day Range
$0.56
MA: $0.64▼
$0.70
52-Week Range
$0.29
Now: $0.69▼
$1.06
Volume348,800 shs
Average Volume515,742 shs
Market Capitalization$46.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is headquartered in Richland, Washington.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.62 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ISR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.isoray.com
Phone509-375-1202

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees43
Outstanding Shares67,651,000
Market Cap$46.36 million
Next Earnings Date9/22/2020 (Estimated)
OptionableNot Optionable
$0.69
0.00 (-0.10 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for ISR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IsoRay (NASDAQ:ISR) Frequently Asked Questions

How has IsoRay's stock price been impacted by Coronavirus (COVID-19)?

IsoRay's stock was trading at $0.6706 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ISR stock has increased by 2.2% and is now trading at $0.6853.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of IsoRay?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IsoRay.

When is IsoRay's next earnings date?

IsoRay is scheduled to release its next quarterly earnings announcement on Tuesday, September 22nd 2020.
View our earnings forecast for IsoRay.

Has IsoRay been receiving favorable news coverage?

News articles about ISR stock have been trending negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IsoRay earned a news impact score of -2.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about IsoRay.

Who are some of IsoRay's key competitors?

Some companies that are related to IsoRay include CRH Medical (CRHM), Omega Diagnostics Group (ODX), Milestone Scientific (MLSS), SDI (SDI), Daxor (DXR), Daxor (DXR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), TransEnterix (TRXC), Akers Biosciences (AKR), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Ambu A/S (AMBBY) and Ansell (ANSLF).
View all competitors.

What other stocks do shareholders of IsoRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IsoRay investors own include Avinger (AVGR), Gannett (GCI), Vaxart (VXRT), Arena Pharmaceuticals (ARNA), Athersys (ATHX), Atossa Genetics (ATOS), BRK (BRKK), Diffusion Pharmaceuticals (DFFN), eMagin (EMAN) and Eros International (EROS).

Who are IsoRay's key executives?

IsoRay's management team includes the following people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 58)
  • Mr. Michael L. Krachon, VP of Sales & Marketing (Age 49)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 54)
  • Mr. Jonathan R. Hunt, CFO & Co-Principal Financial Officer (Age 53)
  • Ms. Jennifer Streeter, Interim COO & VP of HR (Age 50)

What is IsoRay's stock symbol?

IsoRay trades on the NASDAQ under the ticker symbol "ISR."

How do I buy shares of IsoRay?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IsoRay's stock price today?

One share of ISR stock can currently be purchased for approximately $0.69.

How big of a company is IsoRay?

IsoRay has a market capitalization of $46.36 million. IsoRay employs 43 workers across the globe.

What is IsoRay's official website?

The official website for IsoRay is www.isoray.com.

How can I contact IsoRay?

The company can be reached via phone at 509-375-1202.

This page was last updated on 8/13/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.